Technology transfer (TT) encompasses a variety of activities that move academic discoveries into the public sector. Part 1 of this 2-part series explored steps in acquisition of intellectual property (IP) rights (e.g., patents and copyrights). Acceptance of federal research funding obligates the recipient institution to: 1) obtain written agreements from employees to report inventions and discoveries and assign them to the institution; 2) disclose inventions to the federal agency supporting the grant; 3) elect title (if they are going to) to the invention within 2 years; and 4) file a patent application within 1 year of election of title. Institutional obligations are summarized in Table 1 (6,7).
P art 1 of this 2-part series explored steps in acquisition of intellectual property (IP) rights (e.g., patents and copyrights) (1) . Part 2 focuses on technology transfer (TT), which encompasses a variety of activities that move academic discoveries into the public sector. Universities have a mission to ensure that their discoveries, inventions, and new science applications lead to useful products and services for the public. A university that is successful in TT has more opportunities for new research collaborations and funding and for the exchange of materials, information, and personnel with private industry, thus enhancing research opportunities for their faculty and students (2) . In fact, faculty candidates are increasingly "interviewing" the technology transfer office (TTO) as part of their diligence process prior to choosing a home institution. Successful TT improves a university's competitiveness with other academic institutions and the private sector to attract and retain top faculty and researchers. TT may produce income from royalties and licenses that can be reinvested in new research and teaching programs, although a recent study by the Brookings Institution indicates that 84% to 87% of universities will not realize enough income to cover the costs of a TTO (3, 4) . In 2003, it was estimated that the average income per license was $66,645, and that 43% of licenses earned no royalties at all (5).
Acceptance of federal research funding obligates the recipient institution to: 1) obtain written agreements from employees to report inventions and discoveries and assign them to the institution; 2) disclose inventions to the federal agency supporting the grant; 3) elect title (if they are going to) to the invention within 2 years; and 4) file a patent application within 1 year of election of title. Institutional obligations are summarized in Table 1 (6,7).
The U.S. government retains some rights to all federally funded inventions from universities and other nonprofit organizations, as summarized in Table 2 (6, 8, 9) .
A successful TTO manages IP assets through knowledge of IP, licensing, and contract law; an understanding of business management and practicalities; and connections to outside industrial and investment communities (10) . Table 3 lists the top 10 U.S. universities according to number of patents (11) . The TTO must furthermore carry out its tasks within the overall institutional context in which it operates-resolving conflicts between its internal activities and the academic and public missions of the university.
THE TT PROCESS
DISCLOSURE AND PATENTS. TT begins when the inventor discloses an invention to the university (although proactive TTO engagement may start even earlier). Initial steps in the TTO are to determine whether the invention is patentable; whether to take title to the invention and file a patent application; and the practical aspects of the patent application, such as whether funds are available for the application and how quickly the patent application must be filed. Figure 1 shows a simplified overview of the commercialization process.
Considerations regarding whether to file a patent application include whether the discovery is patentable; what the likely uses of a discovery are; whether a discovery has "sufficient" commercial potential; whether significant additional investment (research, development, regulatory approval steps, marketing, and so on) is needed; and (in some institutions) whether the discovery is something without significant commercial value, but nevertheless has potential for social impact through noncommercial channels.
The decision that an invention has "sufficient" potential commercial value for a patent application varies from university to university and depends on many factors. One consideration is the anticipated future royalty revenue of the license. Stanford's Office of Technology Licensing, for example, reportedly often refuses to patent inventions that are not anticipated to eventually generate at least $100,000/year in royalties (7) . Another factor is whether a commercial entity is already interested in the discovery and is capable of developing it. Inventions arising under sponsored research agreements (SRAs) (i.e., grants associated with commercial companies) are often subsequently developed by the sponsoring company.
In other cases, the inventor may know of commercial entities that are engaged in similar research or that have related or complementary products. A third factor is how broad or enforceable the resulting patent is likely to be, and whether copyright is a more suitable IP tool. For instance, if the invention's patentability is doubtful but includes copyrightable subject matter and is otherwise very marketable, it may be best for the institution financially and for the scientific community in general to immediately license the invention without patent protection. The National Institutes of Health (NIH) developed streamlined processes by which TTOs may license nonpatented inventions created with NIH funds to ensure that the scientific community will have expedited access to needed research tools ( (7, 14) .
Assuming a patent will be sought, the TTO will then partner with the inventor to market the patent to find a licensee (or even establish a new commercial entity to be the licensee) and, as is necessary in most cases, provide resources for technology derisking to increase its marketability. This process often begins as soon as a patent application is submitted, because patent application can take 2 to 5 years. It is generally in the university's interest to involve commercial entities as early as possible in the development process to be able to recoup the costs of obtaining a patent as well as to support any additional research that is required before product development can proceed. For example, the research necessary to obtain market approval for new drugs typically takes about 12 years (16); thus, the right investor must have 
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A P R I L 2 0 1 7 : 1 9 7 -2 0 8 a long product-planning horizon to even consider investing in a university-based drug patent. Investing companies with appropriate planning horizons benefit from investing early (by purchasing a product license), because it protects them from competition during product development and launch (6) .
To match appropriate investors with products, a successful TTO understands the fields in which the university is productively inventing, and develops knowledge about and relationships with commercial entities whose unmet needs tend to lie in those fields. Obtain written agreements with employees to disclose discoveries and assign them to the institution.
Disclose invention to the federal agency providing support within 2 months of employee disclosure.
Elect title (if they are going to) within 2 years after federal disclosure.
File a patent application within 1 year after election of title.
Include a statement with patent application that the U.S. government has rights to the invention and identifying the federal agency providing support.
Submit a confirmatory license to the federal agency providing support.
Notify the federal agency within 10 months of filing of the application and countries in which the patent will be pursued.
Submit periodic reports annually to the funding agency regarding use of the invention.
Give preference to issuing licenses to small businesses if they have the resources and capability to commercialize the invention.
NOT assign the rights to inventions to third parties, including the inventor, without prior approval of the funding agency.
Require any exclusive licensee to substantially manufacture within the United States any product that will be sold in the United States, unless this requirement is waived by the funding agency.
Share with the inventor a portion of any income the institution receives from licensing of the invention.
Use the balance of income from licensing of the invention (after costs of patent and license processes are reimbursed) to support education and research. Rights to a nonexclusive, nontransferable, irrevocable, paid-up license to the invention, to practice it or have it practiced on its behalf throughout the world.
Can require the university to assign title to the government if the university fails to report the invention, does not elect title, or does not file for patent within the required period of time.
Can require the university to license the invention to third parties (including the right to require the university to cancel existing exclusive licenses), or the right of the government itself to grant those license (so-called "march-in rights"), provided 1 of the following circumstances occurs: 1) the invention has not been brought into public use within a reasonable time; 2) where health or safety needs are not being met; or 3) where the U.S. manufacturing requirement has not been met and was not waived by the funding agency.
Can make a Determination of Exceptional Circumstances that there are compelling reasons why the right of the university to retain title should be restricted or eliminated. researchers contemplating employment by a particular university should familiarize themselves with the breadth and type of personal contacts within the TTO. A list of some basic questions for researchers to ask their TTO is included in Table 5 .
Once possible licensees are identified, the TTO helps to select the licensee (if there is more than 1 possible qualified investor) and negotiates the license.
NEGOTIATING THE LICENSE. Factors that the TTO will consider in negotiating the license include the type of technology, the perceived risk of the technology, the current stage of development of the discovery, the projected cost of bringing a product to Note that the pathway for every innovation may be significantly different, depending on the presumed commercial versus research value of an innovation; whether the innovation was made in the course of a sponsored research agreement; whether the inventor and innovation are likely to be successful small business innovation research (SBIR)/small business technology transfer research (STTR) grant candidates; whether the innovation falls into the "niche" of a venture capital (VC) investment firm or commercial entity; and what resources of the individual technology transfer office (TTO), university, and inventor have, among many other factors.
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A P R I L 2 0 1 7 : 1 9 7 -2 0 8 market, the size of the potential market, the anticipated profit margin, the strength of the patent claims, whether a patent has actually been issued, the prospects for pending patent applications, estimated cost of research that lead to the invention, the scope of the license being issued (e.g., exclusive vs. nonexclusive, geographic scope, and field of use), and known royalty rates for comparable inventions.
Initial licensing fees tend to be lower (<$100,000)- A partial list of common license conditions is included in Table 6 . A TTO may recommend an exclusive licensing agreement with 1 entity, or may Ownership remains with the Provider (of the material).
Provider is not liable for any damages arising from the Recipient's use of the material.
No reimbursement is required of the Recipient, except the Provider's preparation and distribution costs of the material.
No use in humans.
No commercial research use.
No distribution to third parties.
The Recipient must acknowledge the Provider as the source. suggest that separate uses of a particular discovery or 
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A P R I L 2 0 1 7 : 1 9 7 -2 0 8 development agreement (CRADA), the conditions of which are also set forth in the Bayh Dole Act (7, 8) .
CRADAs are similar to licensing agreements between universities and commercial companies, but have special restrictions. CRADA opportunities must be advertised in the Federal Register prior to execution (unless only 1 company would be a qualified partner).
The government must retain a nonexclusive, irrevocable, paid-up license to any CRADA inventions, even if they are manufactured solely by the commercial entity. CRADA partners have only 30 days to contest publication of CRADA data or to prepare a patent application. CRADA partners also have exclusive rights to use CRADA data for drug approval or other regulatory applications (7, 24) . Although all universities expect their faculty to participate in the search for investments through their own contacts, professional meetings, and technology gatherings, some provide more resources than others (37) . In the past, the process to obtain VC funding began with a startup entrepreneur (usually endorsed by the inventor) seeking out and presenting a "pitch" to a VC firm to obtain capital investments.
However, VC relationships are evolving; in the last 10 years, the process has become more collaborative between VC firms and entrepreneurs, with VC firms scanning academia through TTO contacts or professional meetings for new and innovative concepts and discoveries, and then moving proactively to approach inventors and form companies around those innovations (38) .
FUNDING IS ABOUT RELATIONSHIPS. Understanding the motivations of investment firms or individual investors ("angels") is fundamental to the success of a researcher and his or her TTO in securing investment.
In the words of Ellen Rudnick, executive director of the Michael P. Polsky Center for Entrepreneurship at the University of Chicago, "It's not just about money.
It's about chemistry" (39) . The relationship between the researcher and the investing firm is critical. Nelson, cofounder of ARCH Venture Partners, comments that "the biggest mistake faculty members make is to partner with entrepreneurs who are not of the quality or experience that venture investors will accept" (39) . Furthermore, early in development, it is often best to secure funding only for the short term (12 to 18 months) rather than seeking long-term funding that is reassuring, but may require trading away more of the enterprise to achieve. Once the startup has contracted with its first client, long-term funding will often be achievable for terms that are more favorable to the inventor/university.
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In selecting which investors to approach, the STARTUP COMPANIES. In some cases, inventors may decide to form a new company (a "startup") around the innovation that will then develop, market, and sell the discovery (13). Rarely, the inventor himself or herself may even decide to direct or manage the company (sometimes referred to then as a "faculty startup").
Before going the route of a startup, however, a researcher should seriously consider several issues. C a n t h e i n v e n t o r s e p a r a t e h i m s e l f o r h e r s e l f e m o t i o n a l l y f r o m t h e i n v e n t i o n ? Even if the researcher desires personal involvement in the business, at some point he or she will almost certainly need to set company interests ahead of his or her own and rely upon business experts to help take the discovery to the market. technology (e.g., devices, diagnostics, and delivery systems), a well-qualified principal investigator, a reasonable budget, and access to necessary resources
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Commercialization of Academic Inventions and Discoveries (e.g., facilities, analytical instrumentation) (40) . The overall combined success rate for Phase I and Phase II SBIR and STTR grants is 15% to 25% (42) . 
MANAGING CONFLICTS OF INTEREST
